Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Benefits Of Grapefruit

TORY Dental Plans A 'Waste Of Money' Says UK's Leading Oral Health Charity
The British Dental Health Foundation has called into question the basis of a Conservative party pledge to provide free check-ups in primary schools.
generic viagra online
Kidney Damage From Medical Imaging Procedures Can Cause Long-Term Health Problems
Kidney injury that can arise after undergoing certain medical imaging procedures increases a patient"s risk of having a stroke or heart attack over the next year or two, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology (CJASN). The findings indicate that seemingly minor and reversible kidney damage from these common clinical procedures is a serious health threat.
News of the day
62ND World Health Assembly Closes After Passing 15 Resolutions
WHO Member States had earlier agreed to shorten the Assembly from nine to five days in order to allow senior officials to return to their home countries to help oversee preparedness for a possible influenza pandemic.
Health Insurance

Weakening IP Would Threaten R&D Investment

A proposal to dramatically weaken intellectual property legislation could lead to the loss of thousands of high-skill jobs and millions of dollars of global investment in Australian R&D, Medicines Australia chief executive Ian Chalmers said today. "Weakening Australia"s IP regime would have a negative impact on Australian R&D and is fundamentally at odds with the Prime Minister"s own commitment to make innovation a way of life in Australia," Mr Chalmers said. Generic medicines manufacturer Hospira is seeking changes in the IP laws to allow generic copies of innovative medicines to be manufactured for export while those medicines are still patent-protected, effectively cutting short patent life. "The idea has no merit beyond the commercial agenda of a single pharmaceutical company and could spell disaster for medical innovation," Mr Chalmers said. "We are a country that boasts a sustainable competitive advantage in attracting and conducting high-quality, outcomes-oriented R&D. Australia"s pharmaceutical industry alone attracts more than $1 billion a year in global R&D investment. "That investment generates smart jobs, provides highly skilled work for scientists and supports Australia"s aspiration to become a global leader in medical innovation. "Such investment depends heavily on a consistent and predictable business environment with strong protection of IP rights. If predictability is undermined and IP legislation weakened, global companies will seek other investment destinations. "Apart from the potentially disastrous economic ramifications, there are other reasons why weakening Australia"s IP laws would be counterproductive. "It would contravene Australia"s obligations under the World Trade Organisation"s intellectual property laws. It would also likely provoke retaliatory measures by our key trading partners, with possible market access implications for our $4 billion in pharmaceutical exports. "It would damage multi-lateral efforts to implement globally harmonised standards of IP protection. It would also undermine the rights of patent holders in Australia. "From trade, innovation and economic perspectives, a move to effectively shorten patents in Australia would have dramatic consequences. It just doesn"t stack up." Medicines Australia


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009